COMPANY PROFILE: Kerberos Biopharma, Inc.

CED Life Science Conference 2018 - presenting at the Coulter Investment Forum

www.kerberospharma.com
Year Founded: 2013

COMPANY PROFILE
Kerberos has elucidated the crucial role of the chemokine receptor CX3CR1 and its ligand Fractalkine in regulating the seeding and growth of breast cancer cells to skeleton and soft-tissue organs. Kerberos has synthesized novel, potent and selective small-molecule antagonists to target CX3CR1 receptor and have provided pre-clinical validation of their activity in animal models with high translational relevance.

Clinical proof of principle will be obtained in phase-Ib and phase-II clinical studies on Inflammatory Breast Cancer (IBC) patients, as this tumor progresses dramatically faster than adenocarcinoma. IBC is often difficult to diagnose because it does not usually present with a lump. 35% of women are diagnosed with IBC at an advanced stage and with metastatic disease, in contrast to less than 5% of patients with breast adenocarcinoma. As such, the few treatment options available for IBC are not curative and survival rates at five years are very low.

We have developed a series of small molecule CX3CR1 antagonists to be used in combination with the current standard of care, which for IBC include chemotherapy and / or targeted therapy. Kerberos has a potential IND development candidate (FX-68) which is currently being profiled.

FOUNDERS/MANAGEMENT TEAM
Richard Labaudiniere, PhD, Chairman: Former CEO of FoldRx Pharmaceuticals.
Kevin Taylor, CEO: Seasoned Pharma and Biotech corporate development executive officer.
Alessandro Fatatis, MD, PhD, CSO: Professor of Pharmacology and Pathology at Drexel University College of Medicine.
Shawn Bridy, MA, MBA, CFO: Venture Partner for Militia Hill Ventures, Former Head of Business Development for Immunome.
Olimpia Meucci, MD, PhD, Head, Preclinical Development: Professor and Chair, Department of Pharmacology and Physiology & Director, Center of Neuroimmunology and CNS Therapeutics, Institute of Molecular Medicine and Infectious Diseases, at Drexel University College of Medicine.
Joseph Salvino, PhD, Head, Drug Discovery: Professor of Medicinal Chemistry and Scientific Director at The Wistar Institute and Cancer Center.

KEY MILESTONES TO DATE

  • Founders have been awarded over $4.5M in grant and research funding to date
  • Coulter award – Q3 2017
  • SBIR Phase II awarded - September 2017

CONTACT
Kevin Taylor, (610) 570-9279
ktaylor@kerberospharma.com
3001 Market Street, Suite 140, Philadelphia, PA 19104

Learn more about the CED Life Science Conference.